24.29
+3.80%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Legend Biotech
Its shares trade under the ticker LEGN. It has been listed since 4 June 2020. In the fiscal year to 31 December 2025, it reported revenue of $1.03bn and a net loss of $296.8m. At that date it held total assets of $1.73bn and shareholders' equity of $1.00bn.
Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey. The company went IPO on 2020-06-04. The firm is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies including multiple myeloma (MM). The firm have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). The company is also developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL. The firm also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Jun 2020
- Employees
- 2,900
- Head office
- 2101 COTTONTAIL LANE, SOMERSET, NJ, 08873
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Fangliang ZhangChairman of the Board, since 2015
- Dr. Ying HuangChief Executive Officer, Director, since 2019
- Mr. Carlos SantosChief Financial Officer
- Mr. Alan BashPresident - CARVYKTI
- Ms. Ye WangDirector, since 2015
- Ms. Jessie YeungDirector, since 2025
- Dr. Li ZhuDirector
- Dr. Patrick CaseyIndependent Director
- Mr. Tomas HeymanIndependent Director
- Mr. Xiaohui JiIndependent Director
- Mr. Li MaoIndependent Director
- Dr. Peter SaloveyIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 36
- Social
- 85
- Governance
- 65
- Direct emissions (scope 1)
- 770 t
- Energy emissions (scope 2)
- 12,427.69 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Legend Biotech Corp possesses several key strengths that contribute to its success in the market. Notable strengths include:
Weaknesses
- Despite its strengths, Legend Biotech Corp also faces certain weaknesses that could hinder its growth and performance. These weaknesses include:
Opportunities
- Legend Biotech Corp can leverage several opportunities to maximize its market potential and expand its operations. Key opportunities include:
Threats
- Legend Biotech Corp also faces certain threats that pose challenges to its operations and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.